T1	tradename 0 8	ABRAXANE
T2	activeingredient 36 46	paclitaxel
T3	tradename 170 178	ABRAXANE
T4	tradename 242 262	ABRAXANE. ABRAXANE
T5	nanoparticle 290 325	paclitaxel protein-bound particles
T6	corecomposition 355 368	albumin-bound
T7	fdaapprovaldate 394 398	2005
T8	tradename 511 519	ABRAXANE
T9	activeingredient 805 815	PACLITAXEL
T10	tradename 1105 1113	ABRAXANE
T11	chemoclass 1119 1140	microtubule inhibitor
T12	indication 1182 1207	Metastatic breast cancer,
T13	indication 1451 1497	metastatic non-small cell lung cancer (NSCLC),
T14	indication 1649 1690	Metastatic adenocarcinoma of the pancreas
T15	indication 1838 1863	Metastatic Breast Cancer:
T16	tradename 1886 1894	ABRAXANE
T17	dose 1899 1908	260 mg/m2
T18	routeofadministration 1909 1922	intravenously
T19	indication 1969 1996	Non-Small Cell Lung Cancer:
T20	tradename 2019 2027	ABRAXANE
T21	dose 2032 2041	100 mg/m2
T22	routeofadministration 2042 2055	intravenously
T23	tradename 2186 2195	ABRAXANE.
T24	indication 2212 2243	Adenocarcinoma of the Pancreas:
T25	tradename 2266 2274	ABRAXANE
T26	dose 2278 2287	125 mg/m2
T27	routeofadministration 2288 2301	intravenously
T28	tradename 2445 2454	ABRAXANE.
T29	tradename 2489 2497	ABRAXANE
T30	tradename 2581 2589	ABRAXANE
T31	indication 2607 2648	metastatic adenocarcinoma of the pancreas
T32	indication 2721 2763	metastatic adenocarcinoma of the pancreas,
T33	activeingredient 3347 3357	paclitaxel
T34	corecomposition 3372 3385	albumin-bound
T35	tradename 3620 3629	ABRAXANE.
T36	tradename 3717 3725	ABRAXANE
T37	tradename 4010 4018	ABRAXANE
T38	tradename 4062 4070	ABRAXANE
T39	tradename 4276 4284	ABRAXANE
T40	tradename 4357 4365	ABRAXANE
T41	activeingredient 4550 4560	paclitaxel
T42	tradename 4666 4674	ABRAXANE
T43	tradename 4928 4937	ABRAXANE.
T44	tradename 4996 5005	ABRAXANE.
T45	indication 5151 5176	metastatic breast cancer
T46	adversereaction 5181 5350	alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections,
T47	adversereaction 5355 5364	diarrhea.
T48	indication 5433 5438	NSCLC
T49	adversereaction 5443 5522	anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea,
T50	adversereaction 5527 5535	fatigue.
T51	tradename 5604 5612	ABRAXANE
T52	indication 5616 5646	adenocarcinoma of the pancreas
T53	adversereaction 5651 5786	neutropenia, fatigue, peripheral neuropathy, nausea, alopecia, peripheral edema, diarrhea, pyrexia, vomiting, decreased appetite, rash,
T54	adversereaction 5791 5803	dehydration.
T55	company 5858 5877	Celgene Corporation
T56	tradename 6083 6091	ABRAXANE
T57	indication 6444 6468	Metastatic Breast Cancer
T58	indication 6476 6502	Non-Small Cell Lung Cancer
T59	indication 6510 6540	Adenocarcinoma of the Pancreas
T60	indication 6577 6601	Metastatic Breast Cancer
T61	indication 6609 6635	Non-Small Cell Lung Cancer
T62	indication 6643 6673	Adenocarcinoma of the Pancreas
T63	routeofadministration 6851 6862	Intravenous
T64	corecomposition 7104 7111	Albumin
T65	indication 7219 7243	Metastatic Breast Cancer
T66	indication 7281 7307	Non-Small Cell Lung Cancer
T67	indication 7345 7376	Adenocarcinoma of the Pancreas
T68	tradename 7415 7423	ABRAXANE
T69	activeingredient 7435 7445	Paclitaxel
T70	indication 7913 7937	Metastatic Breast Cancer
T71	indication 7946 7972	Non-Small Cell Lung Cancer
T72	indication 7981 8011	Adenocarcinoma of the Pancreas
T73	tradename 8384 8392	ABRAXANE
T74	nanoparticle 8420 8454	paclitaxel protein-bound particles
T75	corecomposition 8483 8496	albumin-bound
T76	tradename 8549 8557	ABRAXANE
T77	tradename 8876 8884	ABRAXANE
T78	corecomposition 9004 9011	albumin
T79	activeingredient 9020 9030	paclitaxel
T80	activeingredient 9162 9172	PACLITAXEL
T81	indication 9217 9241	Metastatic Breast Cancer
T82	tradename 9242 9250	ABRAXANE
T83	indication 9510 9536	Non-Small Cell Lung Cancer
T84	tradename 9537 9545	ABRAXANE
T85	indication 9611 9649	metastatic non-small cell lung cancer,
T86	indication 9766 9796	Adenocarcinoma of the Pancreas
T87	tradename 9797 9805	ABRAXANE
T88	indication 9865 9907	metastatic adenocarcinoma of the pancreas,
T89	indication 9975 9999	Metastatic Breast Cancer
T90	indication 10046 10070	metastatic breast cancer
T91	tradename 10152 10160	ABRAXANE
T92	dose 10164 10173	260 mg/m2
T93	routeofadministration 10187 10200	intravenously
T94	frequency 10217 10231	every 3 weeks.
T95	indication 10237 10263	Non-Small Cell Lung Cancer
T96	tradename 10288 10296	ABRAXANE
T97	dose 10300 10309	100 mg/m2
T98	routeofadministration 10329 10340	intravenous
T99	tradename 10481 10489	ABRAXANE
T100	indication 10526 10556	Adenocarcinoma of the Pancreas
T101	tradename 10581 10589	ABRAXANE
T102	dose 10593 10602	125 mg/m2
T103	routeofadministration 10622 10633	intravenous
T104	tradename 10746 10754	ABRAXANE
T105	tradename 11136 11144	ABRAXANE
T106	indication 11162 11203	metastatic adenocarcinoma of the pancreas
T107	tradename 11271 11279	ABRAXANE
T108	tradename 11758 11766	ABRAXANE
T109	indication 11775 11784	MBC NSCLC
T110	indication 12160 12163	MBC
T111	indication 12166 12197	Metastatic Breast Cancer; NSCLC
T112	indication 12200 12227	Non-Small Cell Lung Cancer.
T113	dose 12418 12427	260 mg/m2
T114	indication 12446 12470	metastatic breast cancer
T115	dose 12474 12483	100 mg/m2
T116	indication 12502 12528	non-small cell lung cancer
T117	indication 12817 12841	Metastatic Breast Cancer
T118	adversereaction 12866 12884	severe neutropenia
T119	tradename 12980 12988	ABRAXANE
T120	dose 13027 13036	220 mg/m2
T121	tradename 13063 13072	ABRAXANE.
T122	adversereaction 13092 13110	severe neutropenia
T123	adversereaction 13114 13140	severe sensory neuropathy,
T124	dose 13185 13194	180 mg/m2
T125	adversereaction 13201 13227	Grade 3 sensory neuropathy
T126	tradename 13336 13344	ABRAXANE
T127	indication 13440 13466	Non-Small Cell Lung Cancer
T128	tradename 13494 13502	ABRAXANE
T129	tradename 14143 14151	ABRAXANE
T130	tradename 14217 14225	ABRAXANE
T131	adversereaction 14230 14262	Grade 3-4 peripheral neuropathy.
T132	tradename 14271 14279	ABRAXANE
T133	adversereaction 14332 14353	peripheral neuropathy
T134	indication 14556 14561	NSCLC
T135	tradename 14604 14612	ABRAXANE
T136	indication 15240 15270	Adenocarcinoma of the Pancreas
T137	indication 15311 15342	adenocarcinoma of the pancreas,
T138	indication 15451 15481	Adenocarcinoma of the Pancreas
T139	tradename 15495 15503	ABRAXANE
T140	indication 15757 15787	adenocarcinoma of the pancreas
T141	indication 15961 15991	Adenocarcinoma of the Pancreas
T142	tradename 16047 16055	ABRAXANE
T143	indication 16755 16785	adenocarcinoma of the pancreas
T144	indication 16890 16920	Adenocarcinoma of the Pancreas
T145	tradename 16944 16952	ABRAXANE
T146	tradename 17518 17526	ABRAXANE
T147	activeingredient 17584 17594	paclitaxel
T148	tradename 17646 17655	ABRAXANE.
T149	tradename 17693 17701	ABRAXANE
T150	activeingredient 17861 17872	paclitaxel,
T151	tradename 17926 17934	ABRAXANE
T152	adversereaction 18135 18149	extravasation,
T153	tradename 18282 18290	ABRAXANE
T154	adversereaction 18345 18371	infusion-related reactions
T155	adversereaction 18429 18455	hypersensitivity reactions
T156	tradename 18511 18520	ABRAXANE.
T157	tradename 18611 18620	ABRAXANE.
T158	tradename 18684 18692	ABRAXANE
T159	routeofadministration 18795 18806	Intravenous
T160	tradename 18823 18831	ABRAXANE
T161	activeingredient 19854 19865	paclitaxel.
T162	tradename 20368 20376	ABRAXANE
T163	tradename 20623 20631	ABRAXANE
T164	tradename 20886 20894	ABRAXANE
T165	tradename 21163 21171	ABRAXANE
T166	tradename 21802 21810	ABRAXANE
T167	activeingredient 22225 22235	paclitaxel
T168	corecomposition 22250 22263	albumin-bound
T169	tradename 22343 22351	ABRAXANE
T170	tradename 22516 22524	ABRAXANE
T171	adversereaction 22620 22643	Bone marrow suppression
T172	adversereaction 22655 22667	neutropenia)
T173	tradename 22718 22727	ABRAXANE.
T174	adversereaction 22750 22771	Grade 3-4 neutropenia
T175	indication 22805 22836	metastatic breast cancer (MBC),
T176	indication 22858 22893	non-small cell lung cancer (NSCLC),
T177	adversereaction 22951 22964	myelotoxicity
T178	indication 23058 23062	MBC)
T179	indication 23090 23095	NSCLC
T180	indication 23104 23122	pancreatic cancer)
T181	tradename 23143 23151	ABRAXANE
T182	tradename 23338 23346	ABRAXANE
T183	tradename 23375 23383	ABRAXANE
T184	indication 23430 23433	MBC
T185	indication 23437 23443	NSCLC.
T186	indication 23462 23466	MBC,
T187	tradename 23512 23520	ABRAXANE
T188	indication 23646 23652	NSCLC,
T189	tradename 23771 23779	ABRAXANE
T190	indication 24086 24117	adenocarcinoma of the pancreas,
T191	tradename 24127 24135	ABRAXANE
T192	adversereaction 24508 24526	Sensory neuropathy
T193	adversereaction 24618 24649	Grade 1 or 2 sensory neuropathy
T194	adversereaction 24709 24735	Grade 3 sensory neuropathy
T195	tradename 24755 24763	ABRAXANE
T196	indication 24811 24835	metastatic breast cancer
T197	indication 24880 24885	NSCLC
T198	tradename 24967 24975	ABRAXANE
T199	adversereaction 25020 25033	Sepsis Sepsis
T200	adversereaction 25077 25088	neutropenia
T201	tradename 25102 25110	ABRAXANE
T202	co-administereddrug 25131 25143	gemcitabine.
T203	adversereaction 25347 25367	febrile neutropenia,
T204	tradename 25378 25386	ABRAXANE
T205	co-administereddrug 25391 25402	gemcitabine
T206	adversereaction 25535 25559	Pneumonitis Pneumonitis,
T207	tradename 25635 25643	ABRAXANE
T208	co-administereddrug 25664 25676	gemcitabine.
T209	adversereaction 25720 25731	pneumonitis
T210	tradename 25746 25754	ABRAXANE
T211	co-administereddrug 25759 25770	gemcitabine
T212	adversereaction 25802 25814	pneumonitis.
T213	adversereaction 25884 25896	pneumonitis,
T214	tradename 25936 25944	ABRAXANE
T215	co-administereddrug 25949 25961	gemcitabine.
T216	adversereaction 25967 25983	Hypersensitivity
T217	adversereaction 26011 26038	hypersensitivity reactions,
T218	adversereaction 26049 26072	anaphylactic reactions,
T219	adversereaction 26127 26152	hypersensitivity reaction
T220	tradename 26156 26164	ABRAXANE
T221	activeingredient 26270 26280	paclitaxel
T222	tradename 26341 26349	ABRAXANE
T223	tradename 26615 26623	ABRAXANE
T224	tradename 26726 26734	ABRAXANE
T225	indication 26771 26812	metastatic adenocarcinoma of the pancreas
T226	corecomposition 27122 27129	Albumin
T227	tradename 27138 27146	ABRAXANE
T228	corecomposition 27156 27163	albumin
T229	corecomposition 27636 27644	albumin.
T230	tradename 27667 27675	ABRAXANE
T231	activeingredient 27755 27765	paclitaxel
T232	corecomposition 27780 27793	albumin-bound
T233	tradename 28133 28142	ABRAXANE.
T234	tradename 28408 28416	ABRAXANE
T235	tradename 28534 28542	ABRAXANE
T236	tradename 28940 28948	ABRAXANE
T237	indication 28952 28976	metastatic breast cancer
T238	adversereaction 28981 29150	alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections,
T239	adversereaction 29155 29163	diarrhea
T240	tradename 29248 29256	ABRAXANE
T241	co-administereddrug 29277 29288	carboplatin
T242	indication 29293 29319	non-small cell lung cancer
T243	adversereaction 29324 29403	anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea,
T244	adversereaction 29408 29415	fatigue
T245	tradename 29491 29499	ABRAXANE
T246	co-administereddrug 29520 29531	carboplatin
T247	indication 29536 29562	non-small cell lung cancer
T248	adversereaction 29567 29573	anemia
T249	adversereaction 29583 29592	pneumonia
T250	tradename 29676 29684	ABRAXANE
T251	adversereaction 29689 29700	neutropenia
T252	adversereaction 29707 29723	thrombocytopenia
T253	adversereaction 29734 29755	peripheral neuropathy
T254	tradename 29828 29836	ABRAXANE
T255	adversereaction 29841 29852	neutropenia
T256	adversereaction 29860 29876	thrombocytopenia
T257	adversereaction 29888 29894	anemia
T258	tradename 29971 29979	ABRAXANE
T259	adversereaction 29991 30002	neutropenia
T260	adversereaction 30010 30026	thrombocytopenia
T261	adversereaction 30038 30044	anemia
T262	tradename 30089 30097	ABRAXANE
T263	co-administereddrug 30118 30129	gemcitabine
T264	indication 30134 30159	pancreatic adenocarcinoma
T265	tradename 30290 30298	ABRAXANE
T266	adversereaction 30303 30438	neutropenia, fatigue, peripheral neuropathy, nausea, alopecia, peripheral edema, diarrhea, pyrexia, vomiting, decreased appetite, rash,
T267	adversereaction 30443 30455	dehydration.
T268	tradename 30502 30510	ABRAXANE
T269	adversereaction 30553 30560	pyrexia
T270	adversereaction 30567 30578	dehydration
T271	adversereaction 30585 30594	pneumonia
T272	adversereaction 30604 30612	vomiting
T273	tradename 30696 30704	ABRAXANE
T274	adversereaction 30709 30730	peripheral neuropathy
T275	adversereaction 30737 30744	fatigue
T276	adversereaction 30754 30770	thrombocytopenia
T277	tradename 30843 30851	ABRAXANE
T278	adversereaction 30856 30867	neutropenia
T279	adversereaction 30878 30899	peripheral neuropathy
T280	tradename 30976 30984	ABRAXANE
T281	adversereaction 30996 31007	neutropenia
T282	adversereaction 31015 31031	thrombocytopenia
T283	adversereaction 31039 31046	fatigue
T284	adversereaction 31053 31074	peripheral neuropathy
T285	adversereaction 31082 31088	anemia
T286	adversereaction 31098 31106	diarrhea
T287	indication 31148 31172	Metastatic Breast Cancer
T288	tradename 31315 31323	ABRAXANE
T289	activeingredient 31327 31337	paclitaxel
T290	indication 31369 31394	metastatic breast cancer.
T291	tradename 31564 31572	ABRAXANE
T292	activeingredient 31605 31615	Paclitaxel
T293	adversereaction 31668 31679	Neutropenia
T294	adversereaction 31740 31756	Thrombocytopenia
T295	adversereaction 31815 31821	Anemia
T296	adversereaction 31864 31874	Infections
T297	adversereaction 31883 31902	Febrile Neutropenia
T298	adversereaction 31909 31927	Neutropenic Sepsis
T299	adversereaction 31940 31948	Bleeding
T300	indication 32167 32192	Metastatic Breast Cancer
T301	tradename 32262 32270	ABRAXANE
T302	dose 32272 32281	260 mg/m2
T303	activeingredient 32303 32313	Paclitaxel
T304	dose 32324 32333	175 mg/m2
T305	adversereaction 32353 32379	Hypersensitivity Reactionc
T306	adversereaction 32465 32476	Bradycardia
T307	adversereaction 32494 32505	Hypotension
T308	adversereaction 32512 32541	Severe Cardiovascular Eventsd
T309	adversereaction 32546 32558	Abnormal ECG
T310	adversereaction 32630 32635	Cough
T311	adversereaction 32642 32649	Dyspnea
T312	adversereaction 32656 32674	Sensory Neuropathy
T313	adversereaction 32719 32726	Myalgia
T314	adversereaction 32729 32739	Arthralgia
T315	adversereaction 32783 32791	Asthenia
T316	adversereaction 32835 32856	Fluid Retention/Edema
T317	adversereaction 32920 32926	Nausea
T318	adversereaction 32987 32995	Vomiting
T319	adversereaction 33050 33058	Diarrhea
T320	adversereaction 33113 33122	Mucositis
T321	adversereaction 33175 33183	Alopecia
T322	adversereaction 33231 33251	Bilirubin Elevations
T323	adversereaction 33259 33290	Alkaline Phosphatase Elevations
T324	adversereaction 33329 33352	Injection Site Reaction
T325	activeingredient 33460 33470	Paclitaxel
T326	adversereaction 33561 33577	hypersensitivity
T327	adversereaction 33585 33628	flushing, dyspnea, chest pain, hypotension)
T328	adversereaction 33784 33795	Neutropenia
T329	indication 33852 33876	metastatic breast cancer
T330	dose 34004 34013	260 mg/m2
T331	activeingredient 34052 34062	paclitaxel
T332	dose 34086 34095	175 mg/m2
T333	adversereaction 34098 34110	Pancytopenia
T334	tradename 34317 34326	ABRAXANE.
T335	tradename 34525 34533	ABRAXANE
T336	tradename 34659 34667	ABRAXANE
T337	activeingredient 34722 34732	paclitaxel
T338	corecomposition 34752 34759	albumin
T339	tradename 35133 35141	ABRAXANE
T340	tradename 36079 36088	ABRAXANE.
T341	tradename 36219 36227	ABRAXANE
T342	tradename 36309 36317	ABRAXANE
T343	tradename 36486 36494	ABRAXANE
T344	tradename 36898 36906	ABRAXANE
T345	tradename 37207 37215	ABRAXANE
T346	tradename 37351 37359	ABRAXANE
T347	activeingredient 37393 37403	paclitaxel
T348	indication 37859 37885	Non-Small Cell Lung Cancer
T349	tradename 37925 37934	ABRAXANE/
T350	activeingredient 37971 37981	paclitaxel
T351	indication 38114 38148	non-small cell lung cancer (NSCLC)
T352	tradename 38198 38206	ABRAXANE
T353	routeofadministration 38230 38241	intravenous
T354	dose 38280 38289	100 mg/m2
T355	activeingredient 38334 38344	Paclitaxel
T356	routeofadministration 38378 38389	intravenous
T357	dose 38425 38435	200 mg/m2,
T358	routeofadministration 38552 38565	intravenously
T359	tradename 38616 38625	ABRAXANE/
T360	activeingredient 38625 38635	paclitaxel
T361	activeingredient 38665 38675	paclitaxel
T362	tradename 39287 39295	ABRAXANE
T363	activeingredient 39324 39334	paclitaxel
T364	tradename 39558 39566	ABRAXANE
T365	tradename 39799 39807	ABRAXANE
T366	activeingredient 39845 39855	paclitaxel
T367	tradename 40080 40088	ABRAXANE
T368	dose 40090 40099	100 mg/m2
T369	frequency 40100 40107	weekly)
T370	activeingredient 40126 40136	Paclitaxel
T371	dose 40148 40157	200 mg/m2
T372	frequency 40158 40172	every 3 weeks)
T373	tradename 40358 40367	ABRAXANE/
T374	activeingredient 40420 40430	paclitaxel
T375	activeingredient 40495 40505	paclitaxel
T376	tradename 40750 40758	ABRAXANE
T377	activeingredient 40837 40847	paclitaxel
T378	tradename 41081 41089	ABRAXANE
T379	dose 41091 41100	100 mg/m2
T380	frequency 41101 41108	weekly)
T381	activeingredient 41133 41143	Paclitaxel
T382	dose 41155 41164	200 mg/m2
T383	frequency 41165 41179	every 3 weeks)
T384	tradename 41714 41722	ABRAXANE
T385	tradename 41994 42003	ABRAXANE.
T386	indication 42039 42069	Adenocarcinoma of the Pancreas
T387	tradename 42131 42139	ABRAXANE
T388	indication 42240 42281	metastatic adenocarcinoma of the pancreas
T389	tradename 42425 42434	ABRAXANE/
T390	tradename 42588 42597	ABRAXANE/
T391	tradename 42688 42696	ABRAXANE
T392	tradename 42896 42904	ABRAXANE
T393	tradename 43297 43306	ABRAXANE/
T394	tradename 43323 43332	ABRAXANE(
T395	dose 43332 43342	125 mg/m2)
T396	tradename 43518 43527	ABRAXANE/
T397	tradename 43633 43642	ABRAXANE/
T398	tradename 43740 43749	ABRAXANE/
T399	tradename 43942 43950	ABRAXANE
T400	tradename 44167 44176	ABRAXANE/
T401	tradename 44230 44238	ABRAXANE
T402	dose 44240 44250	125 mg/m2)
T403	tradename 45930 45939	ABRAXANE/
T404	tradename 46005 46013	ABRAXANE
T405	dose 46015 46025	125 mg/m2)
T406	indication 46595 46625	adenocarcinoma of the pancreas
T407	tradename 46639 46648	ABRAXANE/
T408	tradename 46953 46962	ABRAXANE/
T409	tradename 47162 47170	ABRAXANE
T410	tradename 47209 47217	ABRAXANE
T411	tradename 47328 47344	ABRAXANE-treated
T412	tradename 47402 47410	ABRAXANE
T413	tradename 47485 47494	ABRAXANE/
T414	tradename 47777 47786	ABRAXANE/
T415	tradename 47883 47891	ABRAXANE
T416	tradename 47955 47963	ABRAXANE
T417	activeingredient 47974 47984	Paclitaxel
T418	tradename 48133 48142	ABRAXANE.
T419	activeingredient 48393 48403	paclitaxel
T420	tradename 48444 48453	ABRAXANE.
T421	tradename 48560 48569	ABRAXANE.
T422	tradename 48582 48590	ABRAXANE
T423	activeingredient 48645 48655	paclitaxel
T424	corecomposition 48675 48682	albumin
T425	tradename 48836 48845	ABRAXANE.
T426	tradename 49097 49105	ABRAXANE
T427	activeingredient 49277 49287	paclitaxel
T428	tradename 49335 49344	ABRAXANE.
T429	activeingredient 49590 49600	paclitaxel
T430	tradename 49682 49691	ABRAXANE.
T431	tradename 49790 49798	ABRAXANE
T432	activeingredient 50057 50067	paclitaxel
T433	tradename 50109 50117	ABRAXANE
T434	tradename 50359 50367	ABRAXANE
T435	activeingredient 50519 50529	paclitaxel
T436	tradename 50670 50679	ABRAXANE.
T437	tradename 50760 50768	ABRAXANE
T438	activeingredient 50979 50989	paclitaxel
T439	activeingredient 51067 51077	paclitaxel
T440	activeingredient 51273 51283	paclitaxel
T441	tradename 51509 51518	ABRAXANE.
T442	activeingredient 51876 51886	paclitaxel
T443	tradename 51960 51968	ABRAXANE
T444	activeingredient 52018 52029	paclitaxel,
T445	activeingredient 52230 52240	paclitaxel
T446	tradename 52324 52332	ABRAXANE
T447	tradename 52820 52829	ABRAXANE.
T448	tradename 52889 52897	ABRAXANE
T449	tradename 53222 53231	ABRAXANE.
T450	activeingredient 53251 53261	paclitaxel
T451	corecomposition 53276 53289	albumin-bound
T452	dose 53364 53371	6 mg/m2
T453	dose 53904 53911	3 mg/m2
T454	activeingredient 54038 54048	paclitaxel
T455	activeingredient 54076 54086	Paclitaxel
T456	tradename 54472 54480	ABRAXANE
T457	tradename 54604 54612	ABRAXANE
T458	indication 54634 54659	metastatic breast cancer,
T459	tradename 54806 54815	ABRAXANE.
T460	tradename 54874 54882	ABRAXANE
T461	indication 54931 54958	non-small cell lung cancer,
T462	tradename 55479 55487	ABRAXANE
T463	tradename 55927 55935	ABRAXANE
T464	activeingredient 56156 56166	paclitaxel
T465	tradename 56272 56280	ABRAXANE
T466	tradename 56370 56378	ABRAXANE
T467	indication 56585 56626	metastatic adenocarcinoma of the pancreas
T468	tradename 56775 56783	ABRAXANE
T469	tradename 57177 57185	ABRAXANE
T470	tradename 57347 57355	ABRAXANE
T471	nanoparticle 57383 57417	paclitaxel protein-bound particles
T472	corecomposition 57446 57459	albumin-bound
T473	nanoparticle 57464 57516	paclitaxel formulated as albumin-bound nanoparticles
T474	particlediameter 57560 57575	130 nanometers.
T475	activeingredient 57576 57586	Paclitaxel
T476	tradename 57650 57658	ABRAXANE
T477	inactiveingredient 57759 57774	Sodium Chloride
T478	routeofadministration 57799 57810	intravenous
T479	activeingredient 57861 57871	paclitaxel
T480	corecomposition 57888 57896	albumin)
T481	corecomposition 57931 57938	albumin
T482	inactiveingredient 57951 57967	sodium caprylate
T483	inactiveingredient 57972 57999	sodium acetyltryptophanate)
T484	nanoparticle 58064 58113	paclitaxel formulated as albumin-bound particles.
T485	tradename 58114 58122	ABRAXANE
T486	tradename 58165 58173	ABRAXANE
T487	activeingredient 58177 58188	paclitaxel,
T488	chemoclass 58191 58213	microtubule inhibitor.
T489	activeingredient 58237 58247	paclitaxel
T490	activeingredient 58251 58389	5,20-Epoxy1,2,4,7,10,13-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine. Paclitaxel
T491	activeingredient 58429 58439	Paclitaxel
T492	activeingredient 58510 58520	C47H51NO14
T493	molecularweight 58547 58554	853.91.
T494	tradename 58694 58702	ABRAXANE
T495	chemoclass 58708 58729	microtubule inhibitor
T496	activeingredient 59030 59040	Paclitaxel
T497	activeingredient 59236 59246	paclitaxel
T498	tradename 59288 59296	ABRAXANE
T499	dose 59315 59330	80 to 375 mg/m2
T500	activeingredient 59405 59415	paclitaxel
T501	tradename 59419 59428	ABRAXANE.
T502	routeofadministration 59439 59450	intravenous
T503	tradename 59469 59478	ABRAXANE,
T504	activeingredient 59479 59489	paclitaxel
T505	dose 59822 59837	80 to 300 mg/m2
T506	activeingredient 59866 59876	paclitaxel
T507	tradename 59881 59889	ABRAXANE
T508	routeofadministration 59926 59937	intravenous
T509	dose 59983 59992	260 mg/m2
T510	tradename 59993 60001	ABRAXANE
T511	dose 60081 60090	175 mg/m2
T512	activeingredient 60091 60101	paclitaxel
T513	tradename 60215 60223	ABRAXANE
T514	activeingredient 60233 60243	paclitaxel
T515	tradename 60329 60337	ABRAXANE
T516	activeingredient 60384 60394	paclitaxel
T517	activeingredient 60553 60563	paclitaxel
T518	tradename 60604 60612	ABRAXANE
T519	activeingredient 60644 60654	paclitaxel
T520	activeingredient 60724 60734	paclitaxel
T521	tradename 60740 60748	ABRAXANE
T522	activeingredient 60777 60788	paclitaxel,
T523	activeingredient 60887 60897	paclitaxel
T524	activeingredient 61065 61076	paclitaxel.
T525	volumeofdistribution 61127 61134	1741 L;
T526	activeingredient 61240 61251	paclitaxel.
T527	activeingredient 61339 61349	paclitaxel
T528	activeingredient 61548 61558	paclitaxel
T529	activeingredient 62032 62042	paclitaxel
T530	dose 62255 62271	80 to 300 mg/m2,
T531	activeingredient 62300 62310	paclitaxel
T532	clearance 62323 62339	13 to 30 L/h/m2,
T533	plasmahalflife 62384 62399	13 to 27 hours.
T534	dose 62431 62440	260 mg/m2
T535	tradename 62450 62459	ABRAXANE,
T536	activeingredient 62905 62915	paclitaxel
T537	tradename 62926 62934	ABRAXANE
T538	activeingredient 63180 63191	paclitaxel.
T539	activeingredient 63427 63437	paclitaxel
T540	activeingredient 63477 63487	paclitaxel
T541	activeingredient 63691 63701	paclitaxel
T542	tradename 64004 64012	ABRAXANE
T543	indication 64129 64170	metastatic adenocarcinoma of the pancreas
T544	activeingredient 64488 64498	paclitaxel
T545	tradename 64509 64517	ABRAXANE
T546	activeingredient 64726 64736	paclitaxel
T547	tradename 64843 64851	ABRAXANE
T548	activeingredient 65117 65128	paclitaxel.
T549	tradename 65168 65176	ABRAXANE
T550	tradename 65263 65271	ABRAXANE
T551	indication 65298 65303	NSCLC
T552	activeingredient 65351 65361	paclitaxel
T553	activeingredient 65577 65588	paclitaxel.
T554	tradename 65731 65739	ABRAXANE
T555	tradename 65793 65801	ABRAXANE
T556	tradename 65967 65975	ABRAXANE
T557	activeingredient 65999 66009	Paclitaxel
T558	tradename 66122 66130	ABRAXANE
T559	activeingredient 66223 66233	paclitaxel
T560	corecomposition 66248 66261	albumin-bound
T561	dose 66691 66705	3 and 12 mg/m2
T562	frequency 66705 66710	/week
T563	activeingredient 66918 66928	paclitaxel
T564	corecomposition 66943 66956	albumin-bound
T565	dose 67026 67034	54 mg/m2
T566	dose 67050 67059	175 mg/m2
T567	indication 67096 67120	Metastatic Breast Cancer
T568	tradename 67291 67299	ABRAXANE
T569	indication 67303 67328	metastatic breast cancer.
T570	tradename 67374 67382	ABRAXANE
T571	dose 67437 67446	175 mg/m2
T572	indication 67467 67492	metastatic breast cancer.
T573	dose 67529 67538	300 mg/m2
T574	indication 67583 67608	metastatic breast cancer.
T575	indication 67796 67821	metastatic breast cancer.
T576	tradename 67859 67867	ABRAXANE
T577	dose 67881 67890	260 mg/m2
T578	activeingredient 67925 67935	paclitaxel
T579	dose 67949 67958	175 mg/m2
T580	tradename 68561 68569	ABRAXANE
T581	activeingredient 68790 68800	paclitaxel
T582	indication 68982 69006	Metastatic Breast Cancer
T583	tradename 69014 69022	ABRAXANE
T584	dose 69023 69032	260 mg/m2
T585	activeingredient 69034 69044	Paclitaxel
T586	dose 69055 69064	175 mg/m2
T587	indication 70149 70175	Non-Small Cell Lung Cancer
T588	indication 70282 70308	non-small cell lung cancer
T589	tradename 70320 70328	ABRAXANE
T590	activeingredient 70364 70374	paclitaxel
T591	indication 70467 70494	non-small cell lung cancer.
T592	tradename 70496 70504	ABRAXANE
T593	routeofadministration 70528 70539	intravenous
T594	dose 70578 70587	100 mg/m2
T595	activeingredient 70632 70642	Paclitaxel
T596	routeofadministration 70676 70687	intravenous
T597	dose 70723 70733	200 mg/m2,
T598	routeofadministration 70850 70863	intravenously
T599	tradename 70914 70923	ABRAXANE/
T600	activeingredient 70923 70933	paclitaxel
T601	tradename 71521 71530	ABRAXANE/
T602	activeingredient 71637 71647	paclitaxel
T603	indication 71850 71876	Non-Small Cell Lung Cancer
T604	tradename 71913 71921	ABRAXANE
T605	dose 71923 71932	100 mg/m2
T606	frequency 71933 71940	weekly)
T607	activeingredient 71965 71975	Paclitaxel
T608	dose 71987 71996	200 mg/m2
T609	frequency 71997 72011	every 3 weeks)
T610	indication 72527 72557	Adenocarcinoma of the Pancreas
T611	tradename 72657 72665	ABRAXANE
T612	indication 72741 72783	metastatic adenocarcinoma of the pancreas.
T613	tradename 73420 73429	ABRAXANE/
T614	tradename 73709 73718	ABRAXANE/
T615	tradename 73739 73747	ABRAXANE
T616	dose 73748 73757	125 mg/m2
T617	routeofadministration 73764 73775	intravenous
T618	dose 73828 73838	1000 mg/m2
T619	routeofadministration 73845 73856	intravenous
T620	dose 73973 73983	1000 mg/m2
T621	routeofadministration 73990 74001	intravenous
T622	dose 74101 74111	1000 mg/m2
T623	indication 75202 75232	Adenocarcinoma of the Pancreas
T624	tradename 75251 75260	ABRAXANE(
T625	dose 75260 75270	125 mg/m2)
T626	tradename 75895 75903	ABRAXANE
T627	activeingredient 77639 77649	paclitaxel
T628	tradename 78308 78316	ABRAXANE
T629	tradename 78506 78514	ABRAXANE
T630	tradename 78650 78658	ABRAXANE
T631	tradename 79157 79165	ABRAXANE
T632	tradename 79422 79430	ABRAXANE
T633	company 79793 79812	Celgene Corporation
T634	tradename 79832 79840	ABRAXANE
T635	company 79870 79894	Abraxis BioScience, LLC.
T636	company 79906 79930	Abraxis BioScience, LLC.
T637	company 79954 79977	Abraxis BioScience, LLC
T638	company 80010 80030	Celgene Corporation.
T639	tradename 80224 80232	ABRAXANE
T640	activeingredient 80250 80260	paclitaxel
T641	corecomposition 80314 80327	albumin-bound
T642	tradename 80387 80395	ABRAXANE
T643	tradename 80548 80567	ABRAXANE? ABRAXANE
T644	indication 80740 80767	non-small cell lung cancer,
T645	tradename 81017 81025	ABRAXANE
T646	tradename 81084 81093	ABRAXANE?
T647	tradename 81110 81118	ABRAXANE
T648	tradename 81242 81251	ABRAXANE.
T649	tradename 81300 81309	ABRAXANE?
T650	tradename 81329 81338	ABRAXANE,
T651	tradename 81556 81574	ABRAXANE. ABRAXANE
T652	tradename 81718 81726	ABRAXANE
T653	tradename 81801 81810	ABRAXANE.
T654	tradename 81969 81978	ABRAXANE.
T655	tradename 82050 82058	ABRAXANE
T656	tradename 82143 82151	ABRAXANE
T657	tradename 82529 82538	ABRAXANE?
T658	tradename 82576 82584	ABRAXANE
T659	tradename 82711 82720	ABRAXANE.
T660	tradename 82789 82798	ABRAXANE.
T661	tradename 82836 82844	ABRAXANE
T662	tradename 82881 82889	ABRAXANE
T663	routeofadministration 82914 82925	intravenous
T664	tradename 83021 83030	ABRAXANE.
T665	tradename 83070 83090	ABRAXANE? ABRAXANE
T666	tradename 83173 83181	ABRAXANE
T667	tradename 83443 83451	ABRAXANE
T668	tradename 83632 83640	ABRAXANE
T669	tradename 83890 83898	ABRAXANE
T670	tradename 84152 84160	ABRAXANE
T671	tradename 84231 84239	ABRAXANE
T672	tradename 85033 85042	ABRAXANE.
T673	tradename 85264 85273	ABRAXANE.
T674	tradename 85458 85467	ABRAXANE.
T675	tradename 85585 85593	ABRAXANE
T676	tradename 85709 85718	ABRAXANE?
T677	activeingredient 85739 85749	paclitaxel
T678	corecomposition 85766 85774	albumin)
T679	corecomposition 85801 85808	albumin
T680	inactiveingredient 85821 85837	sodium caprylate
T681	inactiveingredient 85842 85869	sodium acetyltryptophanate)
T682	company 86003 86022	Celgene Corporation
T683	tradename 86041 86049	ABRAXANE
T684	company 86079 86103	Abraxis BioScience, LLC.
T685	company 86115 86139	Abraxis BioScience, LLC.
T686	company 86163 86186	Abraxis BioScience, LLC
T687	company 86219 86239	Celgene Corporation.
